Inhibition of protein aggregation and amyloid formation by small molecules

Current Opinion in Structural Biology

Volumn 30, Issue , 2015, Pages 50-56

  Doig, Andrew J ^a   Derreumaux, Philippe ^b,c  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

^b CNRS   (France)

^c INSTITUT UNIVERSITAIRE DE FRANCE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

1,4 NAPHTHOQUINON 2 YL LEVO TRYPTOPHAN; AMINO ACID; AMYLOID BETA PROTEIN; CLR 01; CURCUMIN; DEXTRO LYSYLLYSYLLEUCYLVALYLPHENYLALANYLPHENYLALANYLALANYLARGINYLARGINYLARGINYLARGINYLALANINE; DEXTRO PROLYLGLYCYLLYSYLLEUCYLVALYLTYROSYLALANINE; EPIGALLOCATECHIN GALLATE; EPSILON VINIFERIN GLUCOSIDE; HOMOTAURINE; ISLET AMYLOID POLYPEPTIDE PEPTIDE; PEPTIDE; POLYPHENOL DERIVATIVE; PROTEIN INHIBITOR; QUINONE DERIVATIVE; REMBER; RESVERATROL; SEN 1269; SEN 1576; SEN 304; UNCLASSIFIED DRUG; BRIDGED COMPOUND; CLR01 COMPOUND; MOLECULAR LIBRARY; ORGANOPHOSPHATE; POLYPHENOL; POLYSACCHARIDE;

ALPHA HELIX; AMINO TERMINAL SEQUENCE; BINDING AFFINITY; BINDING SITE; CARBOXY TERMINAL SEQUENCE; CYTOTOXICITY; DRUG PROTEIN BINDING; HUMAN; NONHUMAN; PROTEIN AGGREGATION; PROTEIN BINDING; PROTEIN CONFORMATION; PROTEIN PROTEIN INTERACTION; REVIEW; SYNAPTOTOXICITY; TOXICITY; ANIMAL; CHEMICAL STRUCTURE; CHEMISTRY; DRUG DEVELOPMENT; GENETICS; METABOLISM; MOLECULAR DYNAMICS; MOLECULAR LIBRARY; MOUSE; PHARMACOLOGY; PROCEDURES; PROTEIN AGGREGATION, PATHOLOGICAL;

MUS MUSCULUS;

AMYLOID BETA-PEPTIDES; ANIMALS; BRIDGED COMPOUNDS; DRUG DISCOVERY; HUMANS; MICE; MOLECULAR DYNAMICS SIMULATION; MOLECULAR STRUCTURE; ORGANOPHOSPHATES; POLYPHENOLS; POLYSACCHARIDES; PROTEIN AGGREGATION, PATHOLOGICAL; QUINONES; SMALL MOLECULE LIBRARIES;

EID: 84920165153     PISSN: 0959440X     EISSN: 1879033X     Source Type: Journal    
DOI: 10.1016/j.sbi.2014.12.004     Document Type: Review

References (47)

1. Spinney L. Alzheimer's disease: the forgetting gene. Nature 2014, 510:26-28.
2. Nguyen P.H., Derreumaux P. Understanding amyloid fibril nucleation and Aβ oligomer/drug interactions from computer simulations. Acc Chem Res 2014, 47:603-611.
3. Lu J.X., Qiang W., Yau W.M., Schwieters C.D., Meredith S.C., Tycko R. Molecular structure of β-amyloid fibrils in Alzheimer's disease brain tissue. Cell 2013, 154:1257-1268.
4. Nussbaum J.M., et al. Prion-like behaviour and tau-dependent cytotoxicity of pyroglutamylated amyloid-β. Nature 2012, 485:651-655.
5. Salloway S., et al. Bapineuzumab 301 and 302 Clinical Trial Investigators. N Engl J Med 2014, 370:322-333.
6. Jagota S., Rajadas J. Synthesis of d-amino acid peptides and their effect on β-amyloid aggregation and toxicity in transgenic Caenorhabditis elegans. Med Chem Res 2013, 22:3991-4000.
7. Sievers S.A., Karanicolas J., Chang H.W., Zhao A., Jiang L., Zirafi O., Stevens J.T., Munch J., Baker D., Eisenberg D. Structure-based design of non-natural amino-acid inhibitors of amyloid fibril formation. Nature 2011, 475:96-100.
8. Taylor M., Moore S., Mayes J., Parkin E., Beeg M., Canovi M., Gobbi M., Mann D.M.A., Allsop D. Development of a proteolytically stable retro-inverso peptide inhibitor of β-amyloid oligomerization as a potential novel treatment for Alzheimer's disease. Biochemistry 2010, 49:3261-3272.
9. Parthsarathy V., et al. A novel retro-inverso peptide inhibitor reduces amyloid deposition, oxidation and inflammation and stimulates neurogenesis in the APPswe/PS1δE9 mouse model of Alzheimer's disease. PLOS ONE 2013, 8:e54769.
10. Yan L.M., Velkova A., Tatarek-Nossol M., Rammes G., Sibaev A., Andreetto E., Kracklauer M., Bakou M., Malideli E., Göke B., Schirra J., Storr M., Kapurniotu A. Selectively N-methylated soluble IAPP mimics as potent IAPP receptor agonists and nanomolar inhibitors of cytotoxic self-assembly of both IAPP and Aβ40. Angew Chem Int Ed Engl 2013, 52:10378-10383.
11. Sinha S., et al. Lysine-specific molecular tweezers are broad-spectrum inhibitors of assembly and toxicity of amyloid proteins. J Am Chem Soc 2011, 133:16958-16969.
12. Acharya S., Safaie B.M., Wongkongkathep P., Ivanova M.I., Attar A., Klarner F.G., Schrader T., Loo J.A., Bitan G., Lapidus L.J. Molecular basis for preventing α-synuclein aggregation by a molecular tweezer. J Biol Chem 2014, 289:10727-10737.
13. Mori T., Koyama N., Segawa T., Maeda M., Maruyama N., Kinoshita N., Hou H., Tan J., Town T. Methylene blue modulates β-secretase reverses cerebral amyloidosis, and improves cognition in transgenic mice. J Biol Chem 2014, 10.1074/jbc.M114.568212.
14. Amijee H., et al. The N-methylated peptide SEN304 powerfully inhibits Aβ(1-42) toxicity by perturbing oligomer formation. Biochemistry 2012, 51:8338-8352.
15. O'Hare E., Scopes D.I.C., Kim E.M., Palmer P., Spanswick D., McMahon B., Amijee H., Nerou E., Treherne J.M., Jeggo R. Novel 5-aryloxypyrimidine SEN1576 as a candidate for the treatment of Alzheimer's disease. Int J Neuropsychopharmacol 2014, 17:117-126.
16. Yang F., et al. Curcumin inhibits formation of amyloid oligomers and fibrils, binds plaques, and reduces amyloid in vivo. J Biol Chem 2005, 280:5892-5901.
17. Sun A.Y., Wang Q., Simonyi A., Sun G.Y. Resveratrol as a therapeutic agent for neurodegenerative diseases. Mol Neurobiol 2010, 41:375-383.
18. Richard T., Poupard P., Nassra M., Papastamoulis Y., Iglésias M.L., Krisa S., Waffo-Teguo P., Mérillon J.M., Monti J.P. Protective effect of e{open}-viniferin on β-amyloid peptide aggregation investigated by electrospray ionization mass spectrometry. Bioorg Med Chem 2011, 19:3152-3155.
19. Kuriyama S., Hozawa A., Ohmori K., Shimazu T., Matsui T., Ebihara S., Awata S., Nagatomi R., Arai H., Tsuji I. Green tea consumption and cognitive function: a cross-sectional study from the Tsurugaya Project 123. Am J Clin Nutr 2006, 83:355-361.
20. Weinreb O., Amit T., Mandel S., Youdim M.B.H. Neuroprotective molecular mechanisms of (-)-epigallocatechin-3-gallate: a reflective outcome of its antioxidant, iron chelating and neuritogenic properties. Genes Nutr 2009, 4:283-296.
21. Ehrnhoefer D.E., Bieschke J., Boeddrich A., Herbst M., Masino L., Lurz R., Engemann S., Pastore A., Wanker E.E. EGCG redirects amyloidogenic polypeptides into unstructured, off-pathway oligomers. Nat Struct Mol Biol 2008, 15:558-566.
22. Lorenzen N., Nielsen S.B., Yoshimura Y., Vad B.S., Andersen C.B., Betzer C., Kaspersen J.D., Christiansen G., Pedersen J.S., Jensen P.H., Mulder F.A., Otzen D.E. How epigallocatechin gallate can inhibit α-synuclein oligomer toxicity in vitro. J Biol Chem 2014, 289:21299-21310.
23. Jiang L., Liu C., Leibly D., Landau M., Zhao M., Hughes M.P., Eisenberg D.S. Structure-based discovery of fiber-binding compounds that reduce the cytotoxicity of amyloid beta. Elife 2013, 2:e00857.
24. Chebaro Y., Derreumaux P. Targeting the early steps of Aβ16-22 protofibril disassembly by N-methylated inhibitors: a numerical study. Proteins 2009, 75:442-452.
25. Middleton C.T., Marek P., Cao P., Chiu C.C., Singh S., Woys A.M., de Pablo J.J., Raleigh D.P., Zanni M.T. Two-dimensional infrared spectroscopy reveals the complex behaviour of an amyloid fibril inhibitor. Nat Chem 2012, 4:355-360.
26. Biesche J., et al. Small-molecule conversion of toxic oligomers to nontoxic β-sheet-rich amyloid fibrils. Nat Chem Biol 2011, 8:93-101.
27. Scherzer-Attali R., et al. Complete phenotypic recovery of an Alzheimer's disease model by a quinone-tryptophan hybrid aggregation inhibitor. PLoS ONE 2010, 5:e11101.
28. Hopping G., Kellock J., Barnwal R.P., Law P., Bryers J., Varani G., Caughey B., Daggett V. Designed α-sheet peptides inhibit amyloid formation by targeting toxic oligomers. Elife 2014, 3:e01681.
29. Novick P.A., Lopes D.H., Branson K.M., Esteras-Chopo A., Graef I.A., Bitan G., Pande V.S. Design of β-amyloid aggregation inhibitors from a predicted structural motif. J Med Chem 2012, 55:3002-3010.
30. Arai T., Araya T., Sasaki D., Taniguchi A., Sato T., Sohma Y., Kanai M. Rational design and identification of a non-peptidic aggregation inhibitor of amyloid-β based on a pharmacophore motif obtained from cyclo[-Lys-Leu-Val-Phe-Phe-]. Angew Chem Int Ed Engl 2014, 53:8236-8239.
31. Richard T., Papastamoulis Y., Waffo-Teguo P., Monti J.P. 3D NMR structure of a complex between the amyloid beta peptide (1-40) and the polyphenol e{open}-viniferin glucoside: implications in Alzheimer's disease. Biochim Biophys Acta 2013, 1830:5068-5074.
32. Wang S.H., Dong X.Y., Sun Y. Thermodynamic analysis of the molecular interactions between amyloid β-protein fragments and (-)-epigallocatechin-3-gallate. J Phys Chem B 2012, 116:5803-5809.
33. Lopez del Amo J.M., Fink U., Dasari M., Grelle G., Wanker E.E., Bieschke J., Reif B. Structural properties of EGCG-induced, nontoxic Alzheimer's disease Aβ oligomers. J Mol Biol 2012, 421:517-524.
34. Zhang T., Zhang J., Derreumaux P., Mu Y. Molecular mechanism of the inhibition of EGCG on the Alzheimer Aβ(1-42) dimer. J Phys Chem B 2013, 117:3993-4002.
35. Tarus B., Nguyen P.H., Berthoumieu O., Faller P., Doig A.J., Derreumaux P. Molecular structure of the NQTrp inhibitor with the Alzheimer Aβ1-28 monomer. Eur J Med Chem 2014, pii:S0223-5234(14):00608-4.
36. Convertino M., Vitalis A., Caflisch A. Disordered binding of small molecules to Aβ(12-28). J Biol Chem 2011, 286:41578-41588.
37. Attanasio F., et al. Carnosine inhibits Aβ42 aggregation by perturbing the H-bond network in and around the central hydrophobic cluster. ChemBioChem 2013, 14:583-592.
38. Zhu M., De Simone A., Schenk D., Toth G., Dobson C.M., Vendruscolo M. Identification of small-molecule binding pockets in the soluble monomeric form of the Aβ42 peptide. J Chem Phys 2013, 139:35101-35110.
39. Chebaro Y., Jiang P., Zang T., Mu Y., Nguyen P.H., Mousseau N., Derreumaux P. Structures of Aβ17-42 trimers in isolation and with five small-molecule drugs using a hierarchical computational procedure. J Phys Chem B 2012, 116:8412-8422.
40. Zhang T., Xu W., Mu Y., Derreumaux P. Atomic and dynamic insights into the beneficial effect of the NQTrp inhibitor on Alzheimer's Aβ1-42 Dimer in terms of aggregation and toxicity. ACS Chem Neurosci 2014, 5:148-159.
41. Young L.M., Cao P., Raleigh D.P., Ashcroft A.E., Radford S.E. Ion mobility spectrometry-mass spectrometry defines the oligomeric intermediates in amylin amyloid formation and the mode of action of inhibitors. J Am Chem Soc 2014, 136:660-670.
42. Li C., Liu M. Protein dynamics in living cells studied by in-cell NMR spectroscopy. FEBS Lett 2013, 587:1008-1011.
43. Lesné S.E., Sherman M.A., Grant M., Kuskowski M., Schneider J.A., Bennett D.A., Ashe K.H. Brain amyloid-β oligomers in ageing and Alzheimer's disease. Brain 2013, 136:1383-1398.
44. Jonsson T., et al. A mutation in APP protects against Alzheimer's disease and age-related cognitive decline. Nature 2012, 488:96-99.
45. Nguyen P.H., Tarus B., Derreumaux P. Familial Alzheimer A2V mutation reduces the intrinsic disorder and completely changes the free energy landscape of the Aβ1-28 monomer. J Phys Chem B 2014, 118:501-510.
46. Lu P., Bai X.C., Ma D., Xie T., Yan C., Sun L., Yang G., Zhao Y., Zhou R., Scheres S.H., Shi Y. Three-dimensional structure of human gamma-secretase. Nature 2014, 512:166-170.
47. Choi S.H., Kim Y.H., Hebisch M., Sliwinski C., Lee S., D'Avanzo C., Chen H., Hooli B., Asselin C., Muffat J., Klee J.B., Zhang C., Wainger B.J., Peitz M., Kovacs D.M., Woolf C.J., Wagner S.L., Tanzi R.E., Kim D.Y. A three-dimensional human neural cell culture model of Alzheimer's disease. Nature 2014, 515:274-278.